Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCU59W)

Drug Name

UNC2025 Drug Info

Synonyms

1429881-91-3; UNC-2025; mrx-6313; (1r,4r)-4-(2-(butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol; CHEMBL3326006; 4-[2-(butylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol; UNC2025A; SCHEMBL14854194; SCHEMBL15978986; SCHEMBL21797957; BDBM350845; BCP16544; EX-A1030; BDBM50055496; MFCD28142874; s9662; AKOS025289796; ZINC210464182; ZINC249857461; CS-3354; SB16838; NCGC00390618-01; NCGC00482875-01; AK171371; AS-52179; DA-44845; HY-12344; US9795606, B4; B8016; FT-0743029; (1r,4r)-4-(2-(butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexan-1-ol; 2109176-09-0; 4-(2-(Butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexan-1-ol; 4beta-[2-(Butylamino)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-7-yl]cyclohexane-1alpha-ol; R6N

Indication

Disease Entry	ICD 11	Status	REF
Glioblastoma of brain	2A00.00	Investigative	[1]

Cross-matching ID

PubChem CID: 73425588
TTD Drug ID: DMCU59W

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tyrosine-protein kinase Mer (MERTK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[2]
ONO-7475	DMV6GX7	Acute leukaemia	2A60	Phase 1/2	[3]
ONO-7475	DMV6GX7	Acute leukaemia	2A60	Phase 1/2	[4]
RXDX-106	DM6NVTR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
MRX-2843	DMM5N8P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
PF-07265807	DMSMNRQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
INCB81776	DMFOXGB	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
LDC1267	DMH7R6L	Discovery agent	N.A.	Investigative	[9]
G749	DMC7HIS	Discovery agent	N.A.	Investigative	[10]
UNC569	DMJL6ZM	Acute lymphoblastic leukaemia	2A85	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase Mer (MERTK)	TTO7LKR	MERTK_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	MerTK as a therapeutic target in glioblastoma. Neuro Oncol. 2018 Jan 10;20(1):92-102.
2	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of Ono Pharmaceutical.
5	National Cancer Institute Drug Dictionary (drug name RXDX106).
6	The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630.
7	National Cancer Institute Drug Dictionary (drug name PF-07265807).
8	A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477.
9	The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014 Mar 27;507(7493):508-12.
10	G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood. 2014 Apr 3;123(14):2209-19.
11	UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther. 2013 Nov;12(11):2367-77.